Differences

This shows you the differences between two versions of the page.

--- home:starting:physician:reluctant [04.15.2019] – [Specific research] sallieq
+++ home:starting:physician:reluctant [07.19.2019] – [Specific research] sallieq
@@ Line 176: / Line 176: @@
 [[home:protocol:olmesartan:#other_benefits_of_olmesartan_in_patients_-_recent_studies|other benefits]]
-OLM refs to print;  for patient with doctor not a member of MPSS
+OLMesartan references to print out;  for patient with doctor not a member of MPSS
-including information about dose relating to body weight, and dose timing
+include information about dose relating to body weight, and dose timing
@@ Line 185: / Line 185: @@
 {{ :home:mp:olmesartan:4hr_6hr_matched.jpg?nolink&300|4 hourly compared to 6 hourly dosing}}
-The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pubmed>long:16508590}}))
+The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pubmed>long:16508590}})) PMID 16508590
 short extract for each research study follows:
-Benefits of RAS blockade with olmesartan treatment are sustained after study discontinued. (({{pubmed>long:24772521}}))
+Benefits of RAS blockade with olmesartan treatment sustained after study discontinued. PMID 24772521.(({{pubmed>long:24772521}}))  //  Implies that immunopathology may occur unpredictably after discontinuing Olmesartan until microbial infection gets the upper hand again.//
-Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (3 mg/kg) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.(in rat)(({{pubmed>long:88888888}}))
+Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (3 mg/kg) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.[in rat](({{pubmed>long:20074257}}))  PMID 20074257
-Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. (({{pubmed>long:19304450}}))
+Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. (({{pubmed>long:19304450}}))   PMID 19304450
-Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating RAS and NF-kappaB pathway blockade lead to cytotoxicity & apoptosis induction against tumour cells in breast cancer (({{pubmed>long:26138656}}))
+Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating RAS and NF-kappaB pathway blockade lead to cytotoxicity & apoptosis induction against tumour cells in breast cancer (({{pubmed>long:26138656}}))  PMID 26138656
 )
-Alzheimer's disease and dementia1 (({{pubmed>long:20068258}}))
+Alzheimer's disease and dementia1 (({{pubmed>long:20068258}}))  PMID 20068258
-prevent migraines (({{pubmed>long:12503978}}))
+prevent migraines (({{pubmed>long:12503978}}))  PMID 12503978
-inhibit liver fibrosis and aid liver healing (({{pubmed>long:12871826}}))
+inhibit liver fibrosis and aid liver healing (({{pubmed>long:12871826}}))  PMID 12871826
-mg/kg olmesartan reduces the inflammatory process and bone loss in rats (({{pubmed>long:88888888}} ))
+mg/kg olmesartan reduces the inflammatory process and bone loss [in rats] (({{pubmed>long:23775504}} )) PMID 23775504
+Olmesartan at a dose of 10 mg/kg prevented the mucosal damage and inflammation associated with 5-FU-induced OM, increasing granulation and tissue repair. [in hamsters] (({{pubmed>long:30125396}})) PMID 30125396
-protect the mitochondria from age-associated damage from oxidation (({{pubmed>long:12709417}}))
+protect the mitochondria from age-associated damage from oxidation (({{pubmed>long:12709417}}))  PMID 12709417
-reduce liver fibrosis (({{pubmed>long:19303015}}))
+reduce liver fibrosis (({{pubmed>long:19303015}}))  PMID 19303015
-treatment of anxiety and stress-related disorders (({{pubmed>long:15837532}}))
+treatment of anxiety and stress-related disorders (({{pubmed>long:15837532}}))  PMID 15837532
-inflammation in myocarditis (({{pubmed>long:16336207}}))
+inflammation in myocarditis (({{pubmed>long:16336207}}))  PMID 16336207
-C-reactive protein, one of the acute phase proteins that increase during systemic inflammation (({{pubmed>long:16939632}}))
+C-reactive protein, one of the acute phase proteins that increase during systemic inflammation (({{pubmed>long:16939632}}))  PMID 16939632
-cytokine damage (({{pubmed>long:88888888}}))
-in circadian rhythms between HR and MAP in CKD: Synchronization between the two rhythms was progressively lost as renal function deteriorated, and Olmesartan partly restored the synchronization (({{pubmed>long:23511341}}))
+cytokine damage (({{pubmed>long:88888888}}))  PMID
-renal protective effects of olmesartan may be better than those of other ARBs (({{pubmed>long:24384547}}))
+in circadian rhythms between HR and MAP in CKD: Synchronization between the two rhythms was progressively lost as renal function deteriorated, and Olmesartan partly restored the synchronization (({{pubmed>long:23511341}}))  PMID 23511341
-olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects (({{pubmed>long:24842388}}))
+renal protective effects of olmesartan may be better than those of other ARBs (({{pubmed>long:24384547}}))  PMID 23511341
+olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects (({{pubmed>long:24842388}}))   PMID 24842388
-* treatment with olmesartan inhibited bone loss (({{pubmed>long:25363367}}))
+* treatment with olmesartan inhibited bone loss (({{pubmed>long:25363367}}))  PMID 25363367
-* olmesartan protects endothelial cells against oxidative stress-mediated cellular injury (({{pubmed>long:25904217}}))
+* olmesartan protects endothelial cells against oxidative stress-mediated cellular injury (({{pubmed>long:25904217}}))  PMID 25904217
-* decreases viability of malignant cell lines(({{pubmed>long:28666209}}))
+* decreases viability of malignant cell lines(({{pubmed>long:28666209}}))  PMID 28666209
-* carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced the volume of larger atherosclerotic plaques (({{pubmed>long:19124398}}))
+* carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced the volume of larger atherosclerotic plaques (({{pubmed>long:19124398}}))  PMID 19124398
-* improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed>long:25891757}}))
+* improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed>long:25891757}}))  PMID 25891757
-* improvement of glycemic control & insulin resistance was only observed in olmesartan group (({{pubmed>long:23303198}}))
+* improvement of glycemic control & insulin resistance was only observed in olmesartan group (({{pubmed>long:23303198}}))  PMID 23303198
-* OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{pubmed>long:25275251}}))
+* OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{pubmed>long:25275251}}))  PMID 25275251
-* prevention of microalbuminuria in patients with type 2 diabetes and hypertension (({{pubmed>long:22418908}}))
+* prevention of microalbuminuria in patients with type 2 diabetes and hypertension (({{pubmed>long:22418908}}))  PMID 22418908
-Recent studies showed treatment with olmesartan inhibited bone loss (({{pubmed>long:25363367}})),
+Recent studies showed treatment with olmesartan inhibited bone loss (({{pubmed>long:25363367}})),   PMID 25363367
-olmesartan protects endothelial cells against oxidative stress-mediated cellular injury (({{pubmed>long:25904217}})),
+olmesartan protects endothelial cells against oxidative stress-mediated cellular injury (({{pubmed>long:25904217}})),   PMID 25904217
-decreases viability of malignant cell lines (({{pubmed>long:28666209}})),
+decreases viability of malignant cell lines (({{pubmed>long:28666209}})),   PMID 28666209
 carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced
-the volume of larger atherosclerotic plaques (({{pubmed>long:19124398}})),
+the volume of larger atherosclerotic plaques (({{pubmed>long:19124398}})),  PMID 19124398
+Observations suggest a positive role in a potentially lower rate of coronary atheroma progression through the administration of olmesartan, an angiotension-II receptor blocking agent, for patients with stable angina pectoris.  (({{pubmed>long:20202514}}))  PMID 20202514
+This study showed that olmesartan reduces angiotensin II and aldosterone levels more effectively than azilsartan.  (({{pubmed>long:27086671}}))   PMID 27086671
+improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed>long:25891757}})),  PMID 25891757
+improvement of glycemic control & insulin resistance was only observed in olmesartan group (({{pubmed>long:23303198}})),  PMID 23303198
+OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{pubmed>long:25275251}}))  PMID 25275251
+we investigated the effects of RNH-6270, an active metabolite of olmesartan, on TNF-α-induced human glomerular EC (HGEC) damage to clarify the renoprotective mechanisms of ARBs. Our findings suggested that olmesartan might have protective effects against TNF-α-induced glomerular EC dysfunction.(({{pubmed>long:    23052181}})) PMID 23052181
+We orally administered olmesartan 1, 3, and 10 mg/kg/day to rats with EAM for 3 weeks. The cardioprotection of olmesartan may be due to suppression of inflammatory cytokines dependent of the hemodynamic modifications.  (({{pubmed>long:15124927}}))  PMID 15124927
+AlphaTau1 receptor blockers, olmesartan and valsartan (10(-9)-10(-6) mol/L) showed a significant reduction on TNF-alpha-induced LDH and NAG release in human renal proximal tubular epithelial cells (({{pubmed>long:    18331441}})) PMID 18331441
+The administration of olmesartan improved blood pressure, insulin, HOMA, visfatin and lipid profile in hypertensive obese women. (({{pubmed>long:21061834}})) PMID 21061834
+These data added to our previous results further provide a mechanistic rationale for olmesartan's antioxidant/anti-inflammatory potential translation, in the long term, toward anti-atherosclerotic/anti-remodeling effects reported by clinical trials. (({{pubmed>long:26240115}})) PMID 26240115
-improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed>long:25891757}})),
+Olmesartan attenuated CTGF induction, reduced perivascular fibrosis and ameliorated cardiac dysfunction in a PO heart. Our results provide insight into the beneficial effects of olmesartan on PO hearts, independent of blood-pressure lowering. [in rat] (({{pubmed>long:20944640}}))  PMID 20944640
+ Wistar-Kyoto rats were treated with high-dose olmesartan (3 mg.kg(-1).day(-1)), low-dose olmesartan (0.3 mg.kg(-1).day(-1)) Low-dose ARB had no anti-inflammatory effects in anti-GBM GN. However, high-dose ARB reduced glomerular infiltration of CD8+ cells and ED1+ macrophages and suppressed necrotizing and crescentic lesions by days 5 to 7 (P < 0.05). In addition, high-dose ARB reduced the numbers of ED3+-activated macrophages, suppressed glomerular TNF-α and IFN-γ production, and downregulated M1-related chemokine and cytokines (monocyte chemoattractant protein type 1, IL-6, and IL-12). High-dose ARB also enhanced ED2+ M2 macrophages by day 7 with upregulation of glomerular IL-4 and IL-13 and augmented CCL17, IL-1 receptor antagonist, and IL-10. We concluded that high-dose ARB inhibits glomerular inflammation by increasing the numbers of M2 macrophages and upregulation of anti-inflammatory cytokines and by suppressing M1 macrophage development with downregulation of M1-related proinflammatory cytokines. (({{pubmed>long:20071465}})) PMID 20071465
-improvement of glycemic control & insulin resistance was only observed in olmesartan group (({{pubmed>long:23303198}})),
+Olmesartan treatment reversed virtually all neuroendocrine and histopathological cardiac changes induced by EAM (We used experimental autoimmune myocarditis in rats) (({{pubmed>long:18408131}})) PMID 18408131
+Treatment with ARB prevents the progression of peritoneal fibrosis and suppresses expression of adhesion molecules in the peritoneum. (({{pubmed>long:14763058}})) PMID 14763058
-OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{pubmed>long:25275251}}))
+( in cultured human renal proximal tubular cells) Olmesartan inhibited the effect of costimulation with ANG II and IL-6 on AGT expression, indicating that AT1R is critical for AGT enhancement by ANG II. Moreover, IL-6R antibody also neutralized the effect, suggesting that these agents exert a synergistic effect, even though they do not independently induce human AGT expression. These findings suggest that AT1R blockers may attenuate the secondary pathophysiological effects of ANG II even though ANG II alone does not exert any direct effects, and this may partially account for the powerful renoprotective effects of AT1R blocker beyond its depressor effect. (({{pubmed>long:18463317}}))  PMID 18463317
+Olmesartan treatment had already significantly reduced serum levels of high-sensitivity C-reactive protein (-15.1%; P<0.05), high-sensitivity tumor necrosis factor-alpha (-8.9%; P<0.02), interleukin-6 (-14.0%; P<0.05), and monocyte chemotactic protein-1 (-6.5%; P<0.01) after 6 weeks of therapy, whereas placebo treatment (ie, blood pressure reduction) had no major effect on inflammation markers. (({{pubmed>long:15313950}}))  PMID 15313950
-Long term treatment Data suggest 40 & 80 mg olmesartan are able to significantly remodel & destiffen the arterial wall material during long-term treatment, partly independently of blood pressure, compared with 20 mg. hyper.ahajournals.org/content/early/2014/07/07/HYPERTENSIONAHA.114.03282.reprint (({{pubmed>long:25001274}}))
+Long term treatment Data suggest 40 & 80 mg olmesartan are able to significantly remodel & destiffen the arterial wall material during long-term treatment, partly independently of blood pressure, compared with 20 mg. hyper.ahajournals.org/content/early/2014/07/07/HYPERTENSIONAHA.114.03282.reprint (({{pubmed>long:25001274}}))   PMID 25001274
@@ Line 294: / Line 321: @@
 {{section>:home:protocol:olmesartan#recent_studies_of_olmesartan_in_patients}}
-{{tag>Starting_the_Marshall_Protocol letters}}
+{{tag>Starting_the_Marshall_Protocol letters resources_for_physicians}}
 ===== Notes and comments =====

home/starting/physician/reluctant.txt · Last modified: 09.14.2022 by 127.0.0.1